异基因造血细胞移植后 TKI 在费城染色体阳性 ALL 中的作用。
Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL.
机构信息
Department of Stem Cell Transplantation and Cellular Therapy and.
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
Blood. 2020 Oct 8;136(15):1786-1789. doi: 10.1182/blood.2019004685.
Abstract
There is a Commentary on this article in this issue.
摘要
本期对这篇文章有评论。
相似文献
1
Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL.异基因造血细胞移植后 TKI 在费城染色体阳性 ALL 中的作用。
Blood. 2020 Oct 8;136(15):1786-1789. doi: 10.1182/blood.2019004685.
2
Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.达沙替尼治疗的异基因造血干细胞移植后复发的费城染色体阳性急性淋巴细胞白血病患者中出现大颗粒淋巴细胞扩增的患者特征。
Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):e47-54. doi: 10.1016/j.clml.2014.09.006. Epub 2014 Sep 28.
3
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?酪氨酸激酶抑制剂用于移植后维持治疗能否改善高危费城染色体阳性白血病患者的预后？
Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):466-471.e1. doi: 10.1016/j.clml.2016.04.017. Epub 2016 May 5.
4
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.酪氨酸激酶抑制剂可改善费城染色体阳性成人急性淋巴细胞白血病患者异基因造血干细胞移植的长期疗效。
Haematologica. 2015 Mar;100(3):392-9. doi: 10.3324/haematol.2014.116954. Epub 2014 Dec 19.
5
Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.Ph+急性淋巴细胞白血病中的酪氨酸激酶抑制剂：现状与展望
Ann Hematol. 2016 Apr;95(5):681-93. doi: 10.1007/s00277-016-2617-y. Epub 2016 Feb 19.
6
Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.费城染色体阳性急性淋巴细胞白血病异基因造血干细胞移植后使用达沙替尼进行维持治疗。
Ann Hematol. 2013 Aug;92(8):1137-9. doi: 10.1007/s00277-012-1670-4. Epub 2013 Jan 11.
7
Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.成人费城染色体阳性急性淋巴细胞白血病中CDKN2基因缺失与酪氨酸激酶抑制剂耐药性之间的相关性
J Hematol Oncol. 2016 Apr 18;9:40. doi: 10.1186/s13045-016-0270-5.
8
Tyrosine Kinase Inhibitor for Treatment of Adult Allogeneic Hematopoietic Stem Cell Transplantation Candidate with Philadelphia-Positive Acute Lymphoblastic Leukemia.酪氨酸激酶抑制剂用于治疗患有费城染色体阳性急性淋巴细胞白血病的成年异基因造血干细胞移植候选者。
Chin Med J (Engl). 2017 Jan 20;130(2):127-129. doi: 10.4103/0366-6999.197976.
9
Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant.当前治疗费城染色体阳性 B 细胞谱系急性淋巴细胞白血病的方法：酪氨酸激酶抑制剂和干细胞移植的作用。
Curr Oncol Rep. 2021 Jun 14;23(8):95. doi: 10.1007/s11912-021-01086-y.
10
Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation.费城染色体阳性急性淋巴细胞白血病：伊马替尼治疗对缓解诱导及异基因干细胞移植的影响
Curr Oncol Rep. 2006 Sep;8(5):343-51. doi: 10.1007/s11912-006-0056-y.
引用本文的文献
1
Improved outcomes over time in patients aged ≥60 years undergoing allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in first complete remission: a large study by the EBMT acute leukemia working party.≥60岁的急性淋巴细胞白血病患者在首次完全缓解后接受异基因造血细胞移植，其长期预后得到改善：欧洲血液与骨髓移植协会急性白血病工作组的一项大型研究
Bone Marrow Transplant. 2025 May 28. doi: 10.1038/s41409-025-02630-1.
2
Comparison of clinical outcomes between preemptive and maintenance therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.急性髓系白血病异基因造血干细胞移植后抢先治疗与维持治疗的临床结局比较。
Int J Hematol. 2025 May 23. doi: 10.1007/s12185-025-04009-w.
3
The Role of Transplant for Philadelphia-positive B-cell Acute Lymphoblastic Leukemia in 2025.2025年移植在费城染色体阳性B细胞急性淋巴细胞白血病中的作用
Curr Oncol Rep. 2025 May 9. doi: 10.1007/s11912-025-01683-1.
4
Editorial: Allogenic hematopoietic cell transplant in hematological malignancies: controversies and perspective.社论：血液系统恶性肿瘤中的异基因造血细胞移植：争议与展望
Front Oncol. 2025 Mar 19;15:1582751. doi: 10.3389/fonc.2025.1582751. eCollection 2025.
5
Tyrosine Kinase Inhibitor Post-Allogeneic Stem Cell Transplantation in Adult Philadelphia-Positive B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions.酪氨酸激酶抑制剂在成人费城染色体阳性B细胞急性淋巴细胞白血病异基因造血干细胞移植后的应用：现状与未来方向
Curr Issues Mol Biol. 2025 Feb 18;47(2):129. doi: 10.3390/cimb47020129.
6
Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity.达沙替尼耐药的通用型嵌合抗原受体T细胞（CAR-T细胞）在宿主免疫细胞存在的情况下增殖并表现出抗肿瘤活性。
Mol Ther. 2025 Apr 2;33(4):1535-1551. doi: 10.1016/j.ymthe.2025.02.012. Epub 2025 Feb 11.
7
Post-transplant TKIs for Ph+ ALL: practices to date and clinical significance.用于Ph+急性淋巴细胞白血病的移植后酪氨酸激酶抑制剂：目前的实践及临床意义
Int J Hematol. 2025 Apr;121(4):494-503. doi: 10.1007/s12185-025-03917-1. Epub 2025 Jan 17.
8
Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.奥雷巴替尼作为费城染色体阳性急性淋巴细胞白血病异基因造血细胞移植后维持治疗的疗效和安全性
Ann Hematol. 2025 Jan;104(1):801-808. doi: 10.1007/s00277-025-06198-0. Epub 2025 Jan 16.
9
Role of Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia in the Contemporary Era.异基因造血干细胞移植在当代费城染色体阳性B细胞急性淋巴细胞白血病中的作用
Cancers (Basel). 2024 Dec 31;17(1):104. doi: 10.3390/cancers17010104.
10
Dasatinib maintenance following allogeneic transplantation in acute myeloid leukemia with KIT mutation.达沙替尼用于KIT突变的急性髓性白血病异基因移植后的维持治疗。
Bone Marrow Transplant. 2025 Jan;60(1):83-85. doi: 10.1038/s41409-024-02425-w. Epub 2024 Oct 8.
本文引用的文献
1
Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.酪氨酸激酶抑制剂在费城染色体阳性急性淋巴细胞白血病异基因移植后的复发预防中的应用：系统评价。
Biol Blood Marrow Transplant. 2020 Mar;26(3):e55-e64. doi: 10.1016/j.bbmt.2019.09.022. Epub 2019 Sep 23.
2
Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.费城染色体阳性急性淋巴细胞白血病移植后酪氨酸激酶抑制剂预防。
Cancer Sci. 2019 Oct;110(10):3255-3266. doi: 10.1111/cas.14167. Epub 2019 Aug 29.
3
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.费城染色体阳性急性淋巴细胞白血病的治疗。
Curr Treat Options Oncol. 2019 Jan 24;20(1):4. doi: 10.1007/s11864-019-0603-z.
4
Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?费城染色体阳性急性淋巴细胞白血病患者的异基因移植：在酪氨酸激酶抑制剂时代是否必不可少？
Best Pract Res Clin Haematol. 2018 Dec;31(4):357-360. doi: 10.1016/j.beha.2018.09.004. Epub 2018 Sep 20.
5
Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.酪氨酸激酶抑制剂在费城染色体阳性急性淋巴细胞白血病患者异基因造血干细胞移植后预防复发中的应用：欧洲血液和骨髓移植学会急性白血病工作组的立场声明。
Cancer. 2016 Oct;122(19):2941-51. doi: 10.1002/cncr.30130. Epub 2016 Jun 16.
6
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.完全分子反应对费城染色体阳性急性淋巴细胞白血病患者生存的影响。
Blood. 2016 Jul 28;128(4):504-7. doi: 10.1182/blood-2016-03-707562. Epub 2016 May 27.
7
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.酪氨酸激酶抑制剂可改善费城染色体阳性成人急性淋巴细胞白血病患者异基因造血干细胞移植的长期疗效。
Haematologica. 2015 Mar;100(3):392-9. doi: 10.3324/haematol.2014.116954. Epub 2014 Dec 19.
8
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.伊马替尼时代至第二代酪氨酸激酶抑制剂时代费城染色体阳性急性淋巴细胞白血病的耐药性和 BCR-ABL 激酶结构域突变：主要变化在于突变类型，而不在于突变参与的频率。
Cancer. 2014 Apr 1;120(7):1002-9. doi: 10.1002/cncr.28522. Epub 2013 Dec 30.
9
The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.伊马替尼治疗对费城染色体阳性成人急性淋巴细胞白血病异基因干细胞移植结局的影响。
Hematology. 2013 May;18(3):151-7. doi: 10.1179/1607845412Y.0000000052. Epub 2013 Jan 29.
10
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.异基因造血干细胞移植后预防性与微小残留病灶触发伊马替尼治疗 BCR-ABL1 阳性急性淋巴细胞白血病的随机比较。
Leukemia. 2013 Jun;27(6):1254-62. doi: 10.1038/leu.2012.352. Epub 2012 Dec 5.
Zotero 插件